About Inoveon
Inoveon is a company based in Oklahoma City (United States) founded in 1998 was acquired by Ifa systems in August 2010. Inoveon has raised $16 million across 1 funding round from investors including Lilly, i2E and CenterPoint Ventures. The company has 10 employees as of December 31, 2022. Inoveon operates in a competitive market with competitors including Sensimed, i-Optics, Implandata, Azul Optics and Diopsys, among others.
- Headquarter Oklahoma City, United States
- Employees 10 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Inoveon Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16 M (USD)
in 1 rounds
-
Latest Funding Round
$16 M (USD), Series B
Jul 30, 2002
-
Investors
Lilly
& 6 more
-
Employee Count
10
as on Dec 31, 2022
-
Acquired by
Ifa systems
(Aug 16, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Inoveon
Inoveon has successfully raised a total of $16M through 1 strategic funding round. The most recent funding activity was a Series B round of $16 million completed in July 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inoveon
Inoveon has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, i2E and CenterPoint Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Health-focused venture capital investments are made in US sectors.
|
Locked | Locked | Locked |
Investor details for Inoveon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inoveon
Investment portfolio details for Inoveon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inoveon
Detailed financials for Inoveon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inoveon Comparisons
Peer comparison for Inoveon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inoveon
Inoveon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sensimed, i-Optics, Implandata, Azul Optics and Diopsys, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A contact lens-based platform for glaucoma monitoring is offered.
|
|
| Locked | Locked | Locked |
i-Optics specializes in providing advanced retina and cornea imaging systems for medical professionals.
|
|
| Locked | Locked | Locked |
Intraocular pressure is monitored continuously via an implantable microsensor.
|
|
| Locked | Locked | Locked |
Device for assessing the eye health against damaging light
|
|
| Locked | Locked | Locked |
Non-invasive visual electrophysiology devices are supplied for ophthalmological diagnosis.
|
Detailed competitors of Inoveon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inoveon
Complete news archive for Inoveon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inoveon
Inoveon was founded in 1998 and raised its 1st funding round 4 years after it was founded.
Inoveon is headquartered in Oklahoma City, United States. It is registered at Oklahoma City, Oklahoma, United States.
Inoveon is a funded company, having raised a total of $16M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Inoveon is 10.
Inoveon Corporation was founded in 1998 in Oklahoma City, United States, within the healthcare sector. Operations focus on detecting, staging, and monitoring eye conditions such as diabetic retinopathy, macular degeneration, and glaucoma. Services encompass iScan for evaluating diabetic retinopathy, alongside patented 3DT imaging technology and the iScore Diabetes Eye Evaluation Service. Acquisition by Ifa Systems took place on January 11, 2011.
Inoveon's top competitors include 2EyesVision, Sensimed and Diopsys.
Inoveon has 7 investors. Key investors include Lilly, i2E, CenterPoint Ventures, Massey Burch Capital, and Prolog Ventures.